Relapse of kala-azar after use of multiple drugs: a case report and brief review of literature.
We present a case of kala-azar infection that recurred in a patient after completion of the standard treatment course of miltefosine, amphotericin B-deoxycholate (short course), and amphotericin B lipid formulations. The patient was cured after continuous amphotericin B-deoxycholate administration for 4 weeks. This is a unique case of relapse following the use of three important drugs. Although amphotericin B-deoxycholate is a second line drug in Nepal, it has shown a satisfactory clinical response with continuous treatment for 4 weeks. Therefore, an extended course of amphotericin B-deoxycholate may be beneficial in patients with resistance to the standard short course and other anti-leishmania drugs.
Everest International Clinic and Research Center, Kathmandu, Nepal.
K
K
Pandey
S B
SB
Pun
B D
BD
Pandey
D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage*; D000981:Antiprotozoal Agents / Q000008:administration & dosage*; D003840:Deoxycholic Acid / Q000008:administration & dosage*; D004338:Drug Combinations; D006801:Humans; D007898:Leishmaniasis, Visceral / Q000188:drug therapy*; D008297:Male; D009390:Nepal; D010767:Phosphorylcholine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D012008:Recurrence; D013997:Time Factors
D000981:Antiprotozoal Agents; D004338:Drug Combinations; D003840:Deoxycholic Acid; D010767:Phosphorylcholine; C039128:miltefosine; D000666:Amphotericin B; C059765:amphotericin B, deoxycholate drug combination